Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Royalty Pharma Ups Its Bid For Elan
by Rick Mullin
April 22, 2013
| A version of this story appeared in
Volume 91, Issue 16
Royalty Pharma has raised its offer to acquire Elan Corp. to $12.00 per share. The new offer values the Irish drugmaker at $7.3 billion, up from the $6.6 billion Royalty offered earlier this year (C&EN, March 4, page 13). Elan, which called Royalty’s initial offer opportunistic, responded last week that it will “give consideration to any formal proposal by any party.” Elan divested all of its pharmaceutical assets in recent years and now makes money only from royalties. New York City-based Royalty, meanwhile, has made a business of acquiring pharmaceutical royalty interests.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter